They Called It Diabetes. They Didn't Tell You It Could Go The Other Way.

I want to start with a question nobody asked you at that appointment.

How long do you think this has been developing?

Because here’s what the research tells us: by the time someone receives a type 2 diabetes diagnosis, they’ve typically had significant insulin resistance for seven to ten years. Their pancreatic beta cells — the ones that produce insulin — have likely already lost close to half their functional capacity. The disease that got named that day didn’t start that day. It built slowly, over years, sending signals along the way that were either missed, minimized, or never connected into a pattern.

I say this not to assign blame to anyone, healthcare workers are working within real constraints, and this is a systemic failure, not an individual one. I say it because I want you to understand the full picture of what you’re dealing with. And because the answer to that question “how long this has been developing?” is also the answer to how much time you have to change the trajectory.

For the majority of people with type 2 diabetes who are still in the earlier stages, with insulin resistance as the primary driver and without significant complications, the biology is still responsive. The window is still open.

This masterclass is for both groups: those who just received a diagnosis and want to understand what it actually means, and those who were told their blood sugar is “a little high” or their A1c is “borderline.” If you’re in the second group, I want to say this directly: you are not fine, you are not pre-anything in the way that word implies safety. You are on a continuum. And the continuum is still reversible where you’re standing.

Part 1: Recognizing the Pattern

The Continuum Nobody Explains

We covered insulin resistance in depth in the third masterclass of this series. The short version: insulin resistance is the state in which your cells stop responding normally to insulin, your pancreas compensates by producing more, and the downstream consequences: elevated blood sugar, inflammation, fat accumulation, and hormonal disruption build over years before any diagnostic threshold gets crossed.

Type 2 diabetes is what happens at the end of that process, when the pancreas can no longer compensate adequately and blood glucose rises past the official cutoff.

Those cutoffs are: fasting glucose at or above 7.0 mmol/L (126 mg/dL) on two occasions, an A1c at or above 6.5%, or a 2-hour glucose at or above 11.1 mmol/L during a glucose tolerance test [1]. What those numbers don’t convey is the decade of biology that preceded them.

An A1c of 6.4% is called prediabetes. An A1c of 6.5% is called diabetes. The biological difference between those two numbers is almost nothing. The clinical management they typically receive is entirely different. That gap is one of the most consequential in primary care.

Here’s what the pattern looks like, well before those numbers are reached:

The slow creep that gets normalized — blood sugar readings of 5.4, then 5.6, then 5.9, then 6.2 across successive years. Each individual result looks only marginally worse than the last. The trajectory gets missed because each appointment addresses the current number, not the direction of travel.

Weight gain concentrated in the abdomen — visceral fat is the most metabolically active fat depot, and it drives insulin resistance directly through inflammatory signals and interference with insulin receptor function. This isn’t a cosmetic concern. It’s a metabolic marker worth tracking.

Fatigue that peaks in the afternoon, especially after eating — post-meal blood sugar spikes cause an exaggerated insulin response, which can then push blood sugar lower than it should be. The mid-afternoon crash that so many people manage with coffee or another snack often has a blood sugar story underneath it.

Recurrent skin infections, slow wound healing, or unusual thirst — these are the classic presentation most people associate with diabetes, but they typically appear when glucose has been elevated for some time. If you have any of these, you are not in early-stage disease.

The cluster that travels together — type 2 diabetes rarely arrives alone. The 2023 AHA/ACC cardiovascular-kidney-metabolic syndrome framework formally recognizes what clinicians have long observed: blood sugar dysregulation, hypertension, dyslipidemia, kidney changes, and cardiovascular risk are not separate problems. They are one system at different stages of dysfunction [2]. If you have more than one, they belong in the same conversation.

The People Most Likely to Be Missed

People with normal weight — type 2 diabetes occurs at normal BMI, particularly in people with high visceral fat relative to lean mass. BMI-based screening misses this group.

Women in perimenopause — the estrogen decline that accompanies the perimenopause transition substantially increases insulin resistance. Women who were metabolically well-regulated in their 30s can shift into prediabetic ranges in their 40s without any other obvious trigger. I see this regularly, and I see how often it gets attributed to stress or aging rather than investigated properly. If your blood sugar shifted in your 40s without obvious explanation, this is worth looking at specifically.

People of South Asian, East Asian, Middle Eastern, and Hispanic heritage — these populations develop insulin resistance and type 2 diabetes at lower BMI thresholds than European-heritage populations. Standard screening criteria calibrated for European populations systematically underscreen these groups [1].

People with PCOS — insulin resistance is present in up to 80% of women with PCOS regardless of body weight, as covered in the hormones masterclass. Without glucose metabolism screening, the metabolic burden of PCOS goes untracked for years.

Part 2: The Conversation That Didn’t Happen

What You Deserved to Hear

There’s a version of the diabetes diagnosis conversation that goes something like this: your A1c is 6.8, you have type 2 diabetes, try to watch what you eat, here’s a metformin prescription, come back in three months.

I understand why it goes that way. The appointment is fifteen minutes. There is a lot to cover. And clinicians are genuinely doing their best within a system that doesn’t give them the time this conversation requires.

But what doesn’t get covered is everything that would actually help you understand and act on what you’ve just been told. What type 2 diabetes actually is at the cellular level. What your specific metabolic drivers are. Why standard dietary advice doesn’t work equally for everyone. What the research says about reversibility. And — most importantly — what that word, reversibility, actually means for you.

The DIRECT trial, published in the Lancet and followed with two-year durability data, showed that intensive dietary intervention produced complete diabetes remission — defined as A1c below 6.5% without medication — in 46% of participants at one year and 36% at two years [3]. These were people who already had type 2 diabetes, not prediabetes. Remission. Not just better management. Remission.

This is not fringe integrative thinking. This is a landmark randomized controlled trial in one of the world’s most respected medical journals. And most people walking out of a diabetes diagnosis appointment never hear about it. That matters.

I also want to acknowledge something that often goes unspoken. Type 2 diabetes carries significant social stigma — the sense that this happened because of personal failure, that the diagnosis reflects something about character or choices. It doesn’t. And beyond being inaccurate, that framing is clinically counterproductive. The 2025 ADA Standards of Care now include psychosocial screening as a formal component of diabetes management specifically because shame, diabetes distress, and depression directly worsen glycemic control and reduce the ability to engage with treatment [1]. Your emotional experience of this diagnosis is not separate from the clinical picture. It is part of it.

The rest of this masterclass — including what a complete diabetes workup should look like beyond A1c, the dietary framework with the best evidence for reversal, the role of continuous glucose monitoring, the medications worth understanding (and why the SGLT2 inhibitors are more than blood sugar drugs), and the full monitoring framework for protecting your kidneys, eyes, heart, and nerves — is available to paid subscribers.

Every piece in this series is written by our clinical team, grounded in peer-reviewed evidence, and built around the questions we hear most often from patients who felt they left their appointment with a label but not a plan.

Book A Consultation

Part 3: What Good Testing Actually Looks Like

Beyond A1c

A1c is an average. It reflects mean blood glucose over approximately three months, weighted toward recent weeks. It’s a useful population screening tool, but as a window into your individual metabolic reality, it has real limits.

A1c can be falsely low in people with certain hemoglobin variants, iron deficiency anemia, or conditions that affect red blood cell turnover. It can be falsely elevated in iron deficiency. Two people with the same A1c can have completely different glucose variability patterns: one relatively flat, one spiking dramatically throughout the day, and the health implications differ. A1c is where we start. It is not where we stop.

A thorough assessment should include:

Fasting glucose and A1c together — for baseline and ongoing monitoring. They don’t always move in parallel and each tells a slightly different part of the story.

Fasting insulin and HOMA-IR — this is still the assessment most people with a diabetes diagnosis have never had. You can have a rising A1c and have no understanding of whether it’s primarily driven by insulin resistance (the cells aren’t responding), beta cell fatigue (the pancreas is struggling to keep up), or both. That distinction changes the treatment approach in meaningful ways.

C-peptide — a marker of insulin production from the pancreas itself. This helps distinguish type 2 diabetes, where insulin production is present but insufficient from conditions that can be misdiagnosed as type 2, particularly LADA.

GAD65 and islet cell antibodies — specifically to screen for Latent Autoimmune Diabetes in Adults (LADA). LADA is significantly underdiagnosed in adults and is often initially mistaken for type 2. If you were diagnosed with type 2 as an adult, particularly if you’re relatively lean or the standard medications aren’t working as expected, these antibody tests belong in your workup. LADA requires a different management approach and progresses to insulin dependence faster when mismanaged.

Continuous glucose monitoring (CGM) — not just for insulin-dependent diabetes anymore. The 2025 ADA Standards of Care support CGM use in type 2 diabetes managed with non-insulin therapies [1], and I recommend it to most of my patients as an early investigative tool. Two weeks of CGM data shows you how specific foods, activities, sleep quality, and stress levels affect your glucose in real time. It makes the abstract concrete. And it changes behavior in ways that a quarterly A1c reading simply cannot.

Urine albumin-to-creatinine ratio (UACR) and eGFR — kidney screening should begin at diagnosis and be repeated annually. Diabetic kidney disease starts as small amounts of protein in the urine — long before kidney function declines — and this is the window where the right interventions can halt or reverse progression [1]. Most patients are not told this has been checked. Ask specifically.

Dilated eye exam — diabetic retinopathy also begins before it causes symptoms. Baseline at diagnosis, then annually. This is in the guidelines. It is also frequently not arranged.

Comprehensive lipid panel — including triglycerides, HDL, and LDL particle size if available. The lipid pattern that accompanies diabetes (high triglycerides, low HDL, small dense LDL particles) carries higher cardiovascular risk than a standard LDL reading conveys [2].

Part 4: What Actually Moves the Needle

The Possibility of Remission

I want to use the word remission deliberately, because I want you to have it as part of how you think about what’s possible.

Remission, defined as A1c below 6.5% for at least three months without medication, is not a fringe outcome. It is a documented, achievable state for a meaningful proportion of people with type 2 diabetes, particularly those in earlier stages [3]. It is not cure, the underlying metabolic vulnerability persists and requires continued attention. But it is a state in which the disease is not active, medications are not required, and the risk of complications is substantially reduced.

The interventions most consistently associated with remission:

Significant weight loss (specifically in the range of 10–15% of body weight) achieved through whatever method is sustainable and appropriate for that individual. The DIRECT trial used intensive dietary intervention. GLP-1 medications and bariatric surgery achieve this most reliably at the higher end [3].

Low-carbohydrate dietary patterns — for people who cannot or prefer not to pursue very low-calorie approaches, well-structured low-carbohydrate eating has produced significant A1c reductions and medication reduction in multiple trials. The mechanism is direct: reducing dietary carbohydrate reduces the glucose burden that the impaired insulin system has to manage. This is not the right approach for everyone, but for insulin-resistant presentations it is mechanistically the most logical starting point.

The Dietary Framework

Rather than a single prescription, here’s what the evidence supports as principles:

Refined carbohydrates and added sugar are the universal first priority. Ultra-processed carbohydrates, sweetened beverages, and refined starches drive post-meal glucose spikes and chronic hyperinsulinemia. Removing these from the daily baseline is relevant regardless of which overall pattern someone follows.

Protein and non-starchy vegetables are the foundation of a meal. Protein has minimal glucose impact and supports satiety and lean mass. Non-starchy vegetables provide fiber that slows glucose absorption and supports gut health. Building meals around these two categories first, before adding carbohydrates, changes the metabolic math substantially.

Whole food carbohydrates are not the same as refined ones. Legumes, intact whole grains, and most whole fruits produce meaningfully lower glucose responses than their refined counterparts, and come with fiber, protein, and micronutrients that modify how they’re metabolized. They are not interchangeable with white bread.

Meal timing is underused. Glucose tolerance is highest in the morning and declines through the day, this is a real circadian metabolic pattern. Eating the largest carbohydrate intake earlier in the day produces lower glucose excursions than the same food eaten at night. Time-restricted eating aligned with earlier hours has shown specific metabolic benefit in insulin resistance and type 2 diabetes.

Food order within a meal changes glucose outcomes. Eating vegetables and protein before carbohydrates produces meaningfully lower post-meal glucose peaks. This is practical, free, and requires no dietary restriction — only sequence. I tell patients this and watch something shift. A tool that costs nothing tends to land differently than another thing to restrict.

Movement as Medicine

Resistance training specifically preserves insulin sensitivity in skeletal muscle. Muscle is the primary site of glucose uptake. More functional muscle mass means more glucose clearance capacity, and this is why resistance training has a direct glucose-lowering effect independent of weight loss. Losing lean mass during rapid weight loss is a specific concern in diabetes management, which is why protein and resistance training go together.

A 10–15 minute walk after meals produces meaningful reductions in post-meal glucose — in some studies comparable to a pharmacological intervention. It’s free, safe, requires no equipment, and is one of the most underutilized tools in diabetes management. I encourage patients to treat it as part of the meal, not optional movement afterward.

The Medications Worth Understanding

Metformin remains the most studied, safest, and most affordable first-line option. Its primary mechanism is reducing glucose production in the liver. It does not cause hypoglycemia. It has emerging evidence for benefits beyond glucose control, including cardiovascular protection and potential effects on longevity pathways. It is genuinely underappreciated and often discontinued too quickly.

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) cause the kidneys to excrete glucose directly into the urine. But their most clinically significant effects in diabetes management are not about blood sugar, they are about organ protection. These medications have demonstrated substantial reductions in hospitalization for heart failure and meaningful slowing of diabetic kidney disease progression, independently of their glucose-lowering effects [2]. The 2025 ADA guidelines strongly support their use in people with type 2 diabetes who have cardiovascular disease or chronic kidney disease, specifically for these protective effects [1]. This is a medication class I think every patient with type 2 diabetes deserves to understand.

GLP-1 receptor agonists (semaglutide, tirzepatide) reduce blood sugar through multiple mechanisms, produce substantial weight loss, and have cardiovascular outcome data showing significant reductions in heart attack and stroke in high-risk patients [1]. In the diabetes context, they are not primarily weight loss medications, they are cardiovascular protection medications that also significantly improve glycemic control and support weight loss.

My clinical approach uses these medications not as a sign that lifestyle intervention has failed, but as tools that address specific mechanisms, often in parallel with lifestyle work, not instead of it. Someone with significant cardiovascular risk and type 2 diabetes does not benefit from delaying an SGLT2 inhibitor while “trying lifestyle first.” The organ protection begins with the medication. The lifestyle work builds the foundation underneath it.

Part 5: Retesting and What to Watch

The 90-Day, Annual, and Ongoing Framework

At 90 days, I want A1c, fasting glucose, and fasting insulin. Is the A1c moving? Is the fasting insulin, the upstream driver, also improving? If the A1c improves but insulin stays elevated, we haven’t addressed the root yet.

Annually: full metabolic panel, urine albumin-to-creatinine ratio, eGFR, liver enzymes, complete lipid panel, blood pressure. Dilated eye exam. Foot examination. These are not optional extras… they are the monitoring that prevents complications from developing undetected [1]. Ask specifically whether each of these has been done.

For anyone on an SGLT2 inhibitor: urinary tract and genital infections are more common with this class — worth knowing and watching for. Monitor kidney function at 3 months after starting, then annually.

For anyone on a GLP-1 agent: gastrointestinal symptoms typically peak in the first 4–8 weeks and improve with careful dose escalation. Protein intake needs active monitoring. Anyone with a personal or family history of medullary thyroid cancer or MEN2 should not be on this class.

Between labs, track energy (particularly post-meal energy), sleep quality, thirst, urinary frequency, exercise tolerance, and any sensory changes in the feet or hands. These are the signals that tell you whether glucose is well-controlled between draws.

Return sooner than scheduled if: symptoms of hypoglycemia develop on medication (shakiness, sweating, confusion), urinary symptoms worsen suddenly, any vision changes occur, or any new foot sores or wounds that are slow to heal. That last one doesn’t wait, diabetic foot wounds can progress quickly and warrant prompt attention.

Where to Go From Here

I opened this piece by asking how long you think this has been developing.

The answer to that question is also the answer to how much time and biological capacity remains for things to change. The disease built over years. So did the opportunity to redirect it. For the majority of people with type 2 diabetes who are reading this, particularly those who are early in the progression, where insulin resistance is still the primary driver, the biology is still listening.

What it responds to is not generic advice to eat better and exercise more. It responds to understanding the mechanisms, addressing the specific drivers that are operating in your particular body, monitoring the right markers, and using every available tool — dietary, pharmacological, and lifestyle — together rather than in sequence.

The appointment was fifteen minutes. This is the rest of the conversation.

And if you want to have that conversation with someone who will actually look at your full picture, we’re here for that.

Book a Consultation with Heal Integrative Wellness